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Abstract
Background: A switch of continuation phase tuberculosis (TB) treatment regimen from Ethambutol (E) and
Isoniazid (H) combination for 6 months (6EH) to Rifampicin (R) and Isoniazid (H) combination for 4 months (4RH)
was recommended. However, the effect of the regimen switch in Ethiopian setting is not known.
Methods: A comparative cross-sectional study among 790 randomly selected new cases of TB (395 each treated
with 4RH and 6EH during the continuation phase) was conducted in nine health centers and one hospital in three
zones in southwestern Ethiopia. Data were abstracted from the standard unit TB register composed of standard case
and treatment outcome definitions. Data were analyzed using STATA version 13 where binary logistic regression
was fitted to identify independent predictors of unsuccessful treatment outcomes at 5 % significance level.
Results: Over all, 695 (88 %) of the patients had a successful treatment outcome with statistically significant difference
(85.3 % vs 90.6 %, p = 0.02) among the 6HE and 4RH regimens, respectively. After adjusting for confounders, 4RH
continuation phase treatment regimen adjusted odds ratio (AOR) [(95 % confidence interval (CI)) 0.55 (0.34,0.89)],
age [AOR (95 % CI 1.02 (1.001,1.022)], rural residence [AOR (95 % CI) 2.1 (1.18,3.75)] Human Immunodeficiency virus (HIV)
positives [AOR (95 % CI) 2.39 (1.12,5.07)] and increased weight at the end of the second month [AOR (95 %
CI 0.28 (0.11,0.72)] independently predicted treatment outcome.
Conclusion: The switch of continuation phase TB treatment regimen from 6EH to 4RH has brought better
treatment outcomes which imply applicability of the recommendation in high prevalent and resource
constrained settings. Therefore, it should be maintained and augmented through further studies on its
impact among the older, rural residents and HIV positives.
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Background
In the history of tuberculosis (TB) control, discovery of
chemotherapy [1] brought about dramatic changes in pa-
tient survival. Before the advent of chemotherapy, 30–40 %
of TB cases used to die within a year and 50–70 % within
5–7 years after the onset of TB illness [2]. Introduction of
chemotherapy resulted in cure and reduction of mortality
for majority of TB cases [1, 3]. However, shortly after the
therapy, resistance to drug and poor adherence by patients
were reported [4]. Consequently, the first standard combin-
ation therapy for 12 months comprised of Thiacetazone
(T), Isoniazid(H) and streptomycin(S) for the first 2 months
(2STH) followed by T and H for 10 months(10TH) was
issued [2]. Subsequent to the introduction of rifampicin (R),
effective short-course chemotherapy regimens for less than
12 months became standard therapy [2, 5–7]. The short-
course regimens comprised of an initial, or bactericidal,
phase called intensive that aimed to kill bacilli and make
patients non infectious and a continuation or sterilizing
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phase which eliminates persisting mycobacteria to
prevent relapse [1, 8]. Thus evidence based combina-
tions of drugs for different categories of cases have
been recommended for the two phases across the
different regimens [5–7].
Introduction of Rifampicin has shortened TB treatment
duration [1, 9]. In 1991, an eight months treatment regi-
men composed of 2 months intensive with Isoniazid(H),
Rifampicin (R), Pyrazinamide(Z) and Ethambutol(E)
(2RHZE/S) and 6 months continuation (6HE) phases were
recommended for all new cases of TB across the world
[6]. To avoid resistance to the most potent drugs, isonia-
zid and rifampcin and ensure patient adherence, directly
observed treatment short course (DOTS) strategy was
launched in 1994 [10]. Later in 2003, a directly observed
intensive phase treatment followed by two continuation
phase regimens, 6 months of isoniazid plus ethambutol
(6HE) or 4 months of isoniazid plus rifampicin (4HR)
were recommended. The 4HR continuation phase treat-
ment regimen needed to be observed throughout the
treatment period whereas the 6EH regimen relied on self
administered treatment [5]. As a result, regimens without
rifampicin had been considered safer in developing
countries owing to irregular treatments and high ab-
sentee rates [1, 5]. However, the latest World Health
Organization (WHO) guideline recommends 2-month
initial phase of (2RHZE) and a 4-month continuation
phase (4RH) for the treatment of virtually all forms
of new TB cases across the globe [7].
The government of Ethiopia has adopted the switch of
4HR continuation phase TB treatment for all new cases
and accommodated in the latest TB treatment guideline
[11]. Though global strategies are relevant, investigation
of the applicability to the local settings is highly
required. A continuation phase treatment with 4HR
regimen elsewhere has demonstrated lower unsuccessful
treatment outcomes and costs as compared to 6EH
continuation phase [12–15]. But well designed studies
evaluating effects of the introduction of 4RH for the
continuation phase TB treatment in high TB burden and
resource limited settings like Ethiopia are limited. Thus,
we compared treatment outcomes of TB cases who
received 4RH and 6EH continuation phase regimens
under routine program condition in high burden and
resource limited setting. Our objective was to compare
baseline patients’ bacteriologic, socio-demographics,
clinical characteristics and treatment outcomes among
those TB patients treated with the 4RH and 6EH con-
tinuation phase treatment regimens.
Methods
Study setting
We conducted this study in ten health facilities (one
hospital and nine health centres) in three remote zones
of Southern Nation Nationalities and Peoples Region
(SNNPR), one of the nine regions in Ethiopia with about
18million population [16]. Ethiopia is among the 22 TB
High Burden Countries (HBC) where 230,000 incident
cases of which 147,592 (64 %) were notified. In the same
year, 16100 deaths and 90 % treatment success among
the smear positives cases registered in 2011 were
reported [17, 18]. The country has adopted and imple-
mented the DOTS strategy for the treatment of all forms
of TB. Accordingly new cases of TB had been treated
with directly observed RHZE combinations for the first
2 months (2RHZE) followed by self administered EH
combinations for six months (6EH) [19]. As of the end
of 2011, the continuation phase treatment was switched
from 6EH to 4RH. Thus the regimen became directly
observed 2RHZE/4RH combinations for all forms of
new TB cases throughout the 6 months treatment
period [11].
The three study Zones, Bench Maji, Kaffa and Sheka
are located at the southwestern border of the SNNPR
where about 2,064,102 peoples reside [16]. The zones (an
administrative unit that liaison weredas with the region)
are organized in to four town administrations and 26
weredas (lowest administrative unit closer to the com-
munity) those have three hospitals and 65 health centers
those provide TB DOTS services for free. However, the
three hospitals and only 27 health centers were provid-
ing TB/Human Immunodeficeincy Virus (HIV) collab-
orative activities [20].
Study design and sampling
A comparative cross-sectional study among TB cases
treated with 2RHZE/6EH and 2RHZE/4RH regimens
was carried out. New cases registered between 2008 and
2014 were eligible of which those aged above 15 years
were studied. Sample size was estimated using the Stat
Calc program of Epi Info version 7 [21] with 95 % confi-
dence level, 80 % power and ratio of 6EH to 4RH (r = 1).
Accordingly, 512 cases (256 from each group) was
required to detect 7 % difference [12] in the proportion
of unsuccessful outcome among the 6EH and 4RH
groups. Finally, considering the design effect of 1.5 and
10 % missing records, a total of 846 cases were required.
The samples were selected through proportional alloca-
tion to the three zones followed by selection of weredas
and health facilities from the zone using probability
proportional to size. The allocation and selection was
made based on total number of cases reported from the
weredas and health facilities during 2008 through 2014.
Lastly, cases from the selected health facilities were
selected randomly using SPSS statistical software using
TB unit number of the cases.
Data were extracted from a standard unit TB register
recommended by the WHO [11, 19, 22] using extraction
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format prepared for the study. Thus patients’ baseline
attributes (age, gender, residence, sputum smear, type of
TB, HIV status) and follow-up measures (sputum smear,
weight, drug regimen and treatment outcomes) were
extracted. The following standard case and outcome
definitions were adopted and used for the study [11, 19].
 New case of TB a patient who never had treatment
for TB, or had been on anti-TB treatment for less
than four weeks in the past
 Other cases are those patients who do not fulfill the
criteria for new, relapse, and return after default or
treatment after failure.
 Cured: a patient whose sputum smear or culture
was positive at the beginning of the treatment but
who was smear or culture-negative in the last month
of treatment and on at least one previous occasion.
 Treatment completed: completed treatment but
does not have a negative sputum smear or culture
result in the last month of treatment and on at least
one previous occasion.
 Treatment failure: a patient whose sputum smear or
culture is positive at 5 months or later during
treatment or patients found to harbor Multidrug
Resistant (MDR) TB strain at any point of time
during the treatment, whether they are smear-negative
or -positive.
 Died: a patient who dies for any reason during the
course of TB treatment.
 Defaulter/loss to follow-up: a patient who has been
on treatment for at least 4 weeks and interrupted
treatment for eight or more consecutive weeks.
 Successful treatment: a treatment that ends up in
cure or treatment completion
 Unsuccessful treatment: a treatment that end up in
treatment default or loss to follow up, treatment
failure or death.
The extracted data were checked for consistency and
completeness and entered in to Epinfo version 7 that
later exported to STATA 12 [23] for analysis. Data were
described separately for the two groups (6EH and 4RH)
using frequencies, mean, standard deviations and tables.
Besides, crude comparisons of the baseline and follow
up measures among the 6EH and 4RH groups were
made using chi square (x2) or t-tests as appropriate.
Subsequently, bivariate and multiple binary logistic regres-
sion analysis were made to compute crude and adjusted
odds ratios respectively between the explanatory and
outcome variables. Multiple logistic regression model was
fitted with those variables having p ≤ 0.2 on bivariate
analysis. Finally, statistical significance was judged at
p < 0.05 and/or 95 % confidence interval (CI) of odds
ratio (OR) excluding one.
Ethical considerations
We received ethical approval from the institutional
review board of the College of Health Sciences at Addis
Ababa University. Accordingly, anonymous patient data
were extracted from routine service registry upon per-
mission from the respective institutions.
Results
Demographic and baseline clinical characteristics
We retrieved 846 patient records of which 790 (93.4 %)
with complete outcome records [395 each treated with
2RHZE/6HE and 2RHZE/4RHregimens respectively]
were described and analyzed. The mean age of the pa-
tients was 30.8 (31.5 vs 30.9 years, p = 0. 5) respectively,
for those treated with 6HE and 4HR (Table 1). More
than half, 56.6 % and 55.7 % of the patients were male
and reside in rural areas, respectively, with no statisti-
cally significant difference among the two groups. With
regard to the patient profile, 86.8 % and 77%were regis-
tered at health center and had pulmonary TB, respect-
ively. Of the patients, 765 (96.8 %) were new cases (378
treated with 6EH vs387 with 4RH regimen) and the rest
((25 (3.2 %) (17 from 6EH vs 8 from 4RH) were trans-
ferred in and other cases treated with new case regimen.
Human Immunodeficiency virus (HIV) test result was
available for 612 (77.5 %) with statistically significant
difference among the two groups [283 (71.6 %) from
6EH and 329 (83.3 %) from 4RH, p < 0.001]. Among
those tested HIV positives, 44 (57.1 %) received either
Cotrimoxazole Prophylactic Therapy (CPT) or Anti-
retroviral Therapy (ART) with no statistically significant
difference among the regimens 24 (64.9 %) from 6EH
and 20 (50 %), p = 0.2.
Patient follow-ups and treatment outcomes
A total of 695 (88 %) of the patients had successful treat-
ment outcomes with statistically significant difference
(85.3 % vs 90.6 %, p = 0.02) among the 6HE and 4RH
groups, respectively (Table 2). A total of, 324 (90.3 %),
208 (85.4 %) and 163 (91.1 %) of pulmonary positive,
pulmonary negative and extra pulmonary TB cases
respectively had successful outcomes with statistically
significant difference, P = 0.03. Besides, statistically sig-
nificant differences in successful outcomes, 64 (83.1 %),
482 (90.1 %) and 149 (83.7 %, p = 0.005 were also found
among HIV positive, HIV negatives and unknown HIV
status TB cases, respectively.
Measurements of patient weight at the end of second,
fifth and sixth/seventh months of treatment were
available for 504 (63.8 %), 145 (18.4 %) and 141 (17.8 %)
respectively. Thus, 368 (46.6 %) or (48.4 % from 6EH and
44.8 % from 4RH, p = 0.4) have gained some amount of
weight at the end of second month of treatment. On
the other hand, of those initially smear positive pulmonary
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TB cases, 78.6 % had undergone sputum follow up exam-
ination at least once after the diagnosis (76.3 % among
6HE and 80.9 % among 4HR, p = 0.3). Thus sputum smear
results at the end of second, fifth and sixth/seventh
months of treatment were available for274 (76.3 %), 184
(51.3 %) and 179 (49.9 %) cases respectively with no statis-
tically significant differences among the 6EH and 4RH
regimens. The majority of the smear positives (69.9 % vs
79.8 % respectively from the 6EH and 4RH regimens, p =
0.4) converted to negative at the end of second month
treatment.
Factors associated with unsuccessful treatment outcomes
In bivariate analysis patient age, residence, zone, weight
change at the end of the second month of treatment,
sputum smear follow-up and continuation phase regimen
are associated with treatment success at p < 0.05. But, in
multivariate analysis 4RH continuation phase treatment
regimen [AOR (95 % CI) 0.55 (0.34,0.89)], patient age
[AOR (95 % CI) 1.02 (1.001,1.022)], rural residence [AOR
(95 % CI) 2.1 (1.18,3.75)], treated at health center [AOR
(95 % CI) 0.37 (0.14,0.97)], HIV positives [AOR (95 % CI
2.38 (1.12,5.07)], gained weight at the end of the second
month [AOR (95 % CI) 0.28 (0.11,0.72)] independently
predicted unsuccessful treatment outcome (Table 3). The
odds of unsuccessful outcome was higher among the
older, rural residents, HIV positives and unknown weight
change at the end of second month treatment. The odds
of having unsuccessful outcome increase by 2 % for every
one year increase in age (AOR = 1.02).On the other hand,
treated with 4RH continuation phase regimen, being
treated at health center and weight gain at the end of
Table 1 Demographic and clinical characteristics of the tuberculosis patients registered between, 2008–2014, Southwest Ethiopia
Variable Continuation phase treatment regimen Total P value
6EH (n = 395)
n (%)
4RH (n = 395)
n (%)
Age (years) Mean ± SDa 31.1 ± 12.9 30.5 ± 11.9 30.8 ± 12.4 0.5
Gender Male 221 (55.9) 226 (57.2) 447 (56.6) 0.7
Female 174 (44.1) 169 (42.8) 343 (43.4)
Residence Urban 175 (44.3) 175 (44.3) 350 (44.3) 1
Rural 220 (55.7) 220 (55.7) 440 (55.7)
Zone Kaffa 106 (26.8) 104 (26.3) 210 (26.6) 0.9
Bench Maji 206 (52.2) 203 (26.3) 409 (51.8)
Sheka 83 (21.0) 88 (22.3) 171 (21.6)
Treatment center Hospital 55 (13.9) 49 (12.4) 104 (13.2) 0.5
Health center 340 (86.1) 346 (87.6) 686 (86.8)
Baseline weight Mean ± SDa 47.6 ± 8.6 48.4 ± 8.5 48 ± 8.5 0.2
Baseline sputum smear Positive 186 (47.1) 173 (43.8) 359 (45.4) 0.6
Negative 151 (38.2) 165 (41.8) 316 (40)
Unknown 58 (14.7) 57 (14.4) 115 (14.6)
Type of TB Pulmonary 303 (76.7 305 (77.2) 608 (77.0) 0.9
Positive 186 (47.1) 173 (43.8) 359 (45.4)
Negative 117 (30.4) 132 (33.4) 252 (31.9)
Extra pulmonary 92 (23.3) 90 (22.8) 179 (23)
HIV status Positive 37 (9.4) 40 (10.1) 77 (9.7) <0.001
Negative 246 (62.3) 289 (73.2) 535 (67.7)
Unknown 112 (28.4) 66 (16.7) 178 (22.5)
Received CPTb (n = 77) Yes 18 (48.6) 17 (42.5) 35 (45.5) 0.6
Received CPT or ARTc (n = 77) Yes 6 (16.2) 6 (15.0) 12 (15.6) 0.8
Received ART (n = 77) Yes 12 (32.4) 9 (22.5) 21 (27.3) 0.3
Baseline sputum smear Positive 186 (47.1) 173 (43.8) 359 (45.4) 0.6
Negative 151 (38.2) 165 (41.8) 316 (40)
Unknown 58 (14.7) 57 (14.4) 115 (14.6)
aStandard deviation,b CPT Cotrimoxazole prophylactic therapy, cART antiretroviral therapy
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second month have lower likelihood of unsuccessful
outcome. Patients put on 4RH continuation phase of
treatment regimen are 45 % less likely to have unsuc-
cessful outcome compared to those put on 6EH regi-
men. Patients treated at health center have about
63 % lower odds of unsuccessful outcome as com-
pared to those treated at hospitals. HIV co infected
TB patients have more than two fold higher risk of
unsuccessful outcomes compared to HIV negatives
(AOR = 2.38). Those patients gained weight at the end
of the second month of treatment have 72 % lower
odds of unsuccessful outcomes compared to those
with reduced or unchanged weight (AOR = 0.28). A
subgroup analysis among smear positive pulmonary
cases showed having a sputum checkup at least once
during treatment independently predicted 96 % lower
odds of unsuccessful outcomes compared to those
unchecked (AOR 0.04 (95 % CI, 0.01–0.12), P < 0.001)
(Additional file 1).
Discussion
Treatment outcomes among TB patients treated with
RHZE for the first 2 months, followed by HE for
6 months (2RHZE/6EH) and RH for 4 months (2RHZE/
4RH) was compared. Both groups of the cases had no
statistically significant difference with respect to socio-
demographic, baseline clinical, bacteriologic and follow
up measures that depict comparability of the groups.
The comparison was made between regimens used
during the continuation phase treatment (4RH vs 6EH).
Thus a lower rate of unsuccessful outcomes was
reported among those treated with 4RH continuation
phase regimen.
A statistically significant difference in treatment out-
comes where lower unsuccessful treatment outcome
(9.4 % vs 14.7 %) was observed among patients treated
with 4RH and 6EH regimen respectively. Similarly, a
study conducted in Nigeria [14] reported higher odds of
unsuccessful outcome among those treated with 6EH.
Table 2 Patient follow-up measures and treatment outcomes of TB patients registered during 2008–2014, Southwest Ethiopia
Variables Continuation phase treatment regimen
6EH (n = 395)
n (%)





Weight at 2nd month Mean ± SD 49.9 ± 8.9 50.8 ± 8.2 50.4 ± 8.6 0.2
Weight at 5th month Mean ± SD 51.4 ± 8.6 51.3 ± 7.3 51.3 ± 7.9 0.9
Weight at 6/7th month Mean ± SD 51.1 ± 8.9 52.5 ± 6.5 51.7 ± 7.9 0.3
Change in weight at 2nd month Not increased 49 (12.4) 61 (15.4) 110 (13.9) 0.4
Increased 191 (48.4) 177 (44.8) 368 (46.6)
Unknown 155 (39.2) 157 (39.7) 312 (39.5)
Sputum smear end of 2nd month (n = 359) Positive 4 (2.2) 2 (1.2) 6 (1.7) 0.09
Negative 130 (69.9) 138 (79.8) 268 (74.7)
Unknown 52 (28) 33 (19.1) 85 (23.7)
Sputum smear end of 5th month (n = 359) Positive 1 (0.5) 0 (0) 1 (0.3) 0.03
Negative 83 (44.6) 100 (57.8) 183 (51)
Unknown 102 (54.8) 73 (42.2) 175 (48.7)
Sputum smear end of 6/7th month (n = 359) Positive 0 0 0 0.8
Negative 94 (50.5) 85 (49.1) 179 (49.9)
Unknown 92 (49.5) 88 (50.9) 180 (50.1)
Sputum smear done during treatment (n = 359) No 44 (23.7) 33 (19.1) 77 (21.4) 0.3
At least once 142 (76.3) 140 (80.9) 282 (78.6)
Continuation phase visit Mean ± SD 5.8 ± 1.1 5.4 ± 3.1 0.09
Treatment outcome Successful 337 (85.3) 358 (90.6) 695 (88) 0.02
Cured 77 (19.5) 85 (21.5) 162 (20.5)
Completed 260 (65.8) 273 (69.1) 533 (67)
Unsuccessful 58 (14.7) 37 (9.4) 95 (12)
Died 28 (7.1) 18 (4.6) 46 (5.8)
Defaulted 29 (7.3) 19 (4.8) 48 (6.1)
Failure 1 (0.3) 0 1 (0.1)
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This could be due to the differences in length and type
of drugs used during the continuation phase treatment
those influence adherence and ultimate outcome. Studies
reported that reduced continuation phase (from 6EH to
4HR) treatment is associated with lower cost and ex-
pected mortality [12] that enhance successful treatment
outcome. On the other hand, use of rifampcin for longer
period of time during the treatment of TB is associated
with better outcomes [13] that might be related with ef-
ficacy of the drug. The finding implies the adoption [11]
of the latest WHO recommendation [7] in high preva-
lent and resource constrained settings is working well.
Apart from the treatment regimens, patient attribute
like age and residence independently predicted treat-
ment outcomes. We found that age had an inverse
relation with unsuccessful outcome where the odds of
unsuccessful outcome increase with age. Several studies
also reported that older patients were more likely to
have unsuccessful outcomes than younger [24–27]. This
could be due to higher risk of age related co morbid
situations those lead to poor adherence and outcomes
[28]. Patients residing in rural areas had higher risk of
unsuccessful outcomes which could be attributed to the
low access to TB care and unfavorable living conditions.
The findings imply need for focused intervention
targeted to those older age groups and rural dwellers
besides the treatment regimen.
Monitoring of patient weight and sputum are among
the recommended follow-up measures required for TB
patients on treatment [7]. The results of both weight and
sputum monitoring are used to adjust for drug dose and
predict outcomes of the treatment. The proportion of
smear positive patients converted to negative at the end of
the intensive phase has been taken among indicators of
TB programme performance [7]. However, only small
proportion of patients had documented results of the
weight and sputum follow-ups particularly at the later pe-
riods of treatment. Consistent to findings from African
settings [29] majority of those patients undergone sputum
checkup during treatment converted to negative.
Patients gained some amount of weight at the end of
second month treatment had lower risk of unsuccessful
outcomes which is consistent with other studies [30, 31].
This could be explained by the fact that weight gain
marks some level of improvement from the TB illness
including reduced appetite. In addition, changes in
weight while on treatment might be an indication of
appropriateness of the drug dose to treat the illness. On
the other hand those with unknown weight change at
the end of first two months treatment had higher odds
Table 3 Factors associated with unsuccessful treatment outcomes among TB patients registered during 2008–2014, Southwestern Ethiopia









Age (years) Mean(SD) 33.5 (14) 30.4 (12.0) 1.02 (1.002,1.03) 1.02 (1.001,1.022)
Gender Male 60 (13.4) 387 (86.6) 1 1
Female 35 (10.2) 308 (89.8) 0.73 (0.47.1.14) 0.63 (0.38,1.03)
Residence Urban 32 (9.1) 318 (90.9) 1 1
Rural 63 (14.3) 377 (85.7) 1.66 (1.06,2.61) 2.1 (1.18,3.75)
Zone Kaffa 34 (16.2) 176 (83.8) 1 1
Bench Maji 50 (12.2) 359 (87.8) 0.72 (0.45,1.14) 1.41 (0.73,2.75)
Sheka 11 (6.4) 160 (93.6) 0.36 (0.17,0.73) 1.2 (0.44,3.32)
Treatment center Hospital 17 (16.3) 87 (83.7) 1 1
HC 78 (11.4) 608 (88.6) 0.66 (0.37,1.16) 0.37 (0.14,0.97)
Type of TB Pulmonary 78 (12.8) 530 (87.2) 1 1
EPTBb 17 (9.3) 165 (90.7) 0.70 (0.40,1.22) 0.57 (0.32,1.04)
HIV status Negative 53 (9.9) 482 (90.1) 1 1
Positive 13 (16.9) 64 (83.1) 1.85 (0.95,3.57) 2.39 (1.12,5.07)
Unknown 29 (16.3) 178 (83.7) 1.77 (1.08,2.88) 2.26 (1.23,4.11)
Weight change end of 2nd month No increase 11 (8.2) 357 (91.8) 1 1
Increased 9 (3) 101 (97) 0.35 (0.14,0.86) 0.28 (0.11,0.72)
Unknown 75 (24) 237 (76) 3.55 (1.71,7.37) 3.48 (1.60,7.54)
Continuation phase regimen 6EH 58 (14.7) 337 (85.3) 1 1
4RH 37 (9.4) 358 (90.6) 0.60 (0.39,0.93) 0.55 (0.34,0.89)
aConfidence interval, bExtra pulmonary Tuberculosis, bold figures indicate statisticaly significant at p<0.05
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of unsuccessful outcomes. This might have occurred due
to possible misclassification of cases with reduced or
remains unchanged to unknown. The weight change
might be unknown due to patients’ treatment interrup-
tion subsequent to treatment default or death those
constitute unsuccessful outcome. So that patient’s status
of weight during treatment might be left undetermined.
Having sputum checkup at least once during treat-
ment among initially smear positives predicted lower
risk of unsuccessful outcome. However, reviews showed
low sensitivity and modest specificity of sputum results
at the end of intensive phase to predict failure and
relapse [32]. On the other hand, detection of sputum
positive during treatment trigger further patient assess-
ment that influence treatment regimens and ultimate
outcome. Hence, the routine sputum monitoring
adopted by the country [11] during treatment should be
improved as it is an indicator of program performance
and trigger for patient assessment.
Consistent with other studies [33, 34], HIV positive TB
patients are more likely to have unsuccessful outcomes
compared to those negatives. This could be due to
multifaceted influences of HIV on TB diagnosis and
response to TB treatment those negatively affect the out-
comes of TB treatment [35]. Consequently, collaborative
services have been recommended in order to curb the
influence of HIV on TB and vice versa [36]. Evidences
from systematic review in African context supported the
recommendation and reported better outcomes among
concurrently screened and managed TB and HIV in-
fected patients [37]. Nonetheless, we found no statisti-
cally significant difference in treatment success among
those infected TB patients provided with CPT and/or
ART. The indifference could be explained by the low up-
take of integrated TB/HIV collaborative services among
the studied patients. In this study, more than three
quarter of the patients were offered HIV test which is
little higher than the national average of 65 % [18] and
9.7 % TB/HIV co infected patients which is almost simi-
lar to the national average of 10 %. However, only few
HIV co infected patients (45 % on CPT and 27.3 % on
ART) were found to have documented service provision.
[18]. The discrepancies could be due to differences in
reporting periods where the national average is a single
year attainment but that of this study is over a period of
six years including the nationally reported year. Over all,
the targets set for the TB/HIV service collaboration has
not yet met which calls for in depth understanding and
focused intervention that suit local settings. On the
other hand, unknown HIV status predicted higher odds
of unsuccessful outcomes. This could be due to possible
misclassification of HIV positive cases those predict
worse outcome in to unknown. The study is limited to
control for changes in medical resources, polices and
quality of care across the study periods. Since only few
variables were captured on the register, we could not
control for possible confounding effect of socio-
economic, lifestyle and co morbid illness. Furthermore
resistance pattern of the treatment regimens could not
be evaluated which is recommended for the assessment
of impact of treatment regimens. On the other hand the
random selection of relatively large sample from both
groups minimized risk of selection bias. The groups
treated with 4RH and 6EH had insignificant differences
with regard to baseline and follow-up clinical and bacte-
riologic attributes that enhanced comparability of the
groups. Besides, we extracted data from a standardized
routine programme register that reflect operational
reality. In general, our study is valid and can apply in
similar settings given the limitations.
Conclusion
In conclusion, the switch of continuation phase TB treat-
ment regimen for new cases from 6EH to 4RH has brought
better treatment outcomes. The findings verified the applic-
ability of latest WHO recommendation and national adop-
tion to the high prevalent and resource constrained
settings. However, the unsuccessful outcome among the
older, rural dwellers and HIV positives is higher independ-
ent of the treatment regimen that need further investigation
and focused intervention. Therefore, the recommended
switch of treatment regimen should be maintained and
progressively assessed for outcomes, including drug resist-
ance survey or surveillance. Moreover, further studies
should be carried out on the impact of treatment regimens
among older, rural residents and HIV positives.
Additional file
Additional file 1: Table 4: Factors associated with unsuccessful treatment
outcome among smear positive pulmonary TB cases registered during
2008-2014, southwestern Ethiopia (n=359). Table 5: Factors associated with
unsuccessful outcome among clinically diagnosed (smear negative 10.1186/
s12879-016-1917-0 pulmonary and extra pulmonary) TB cases registered
during 2008-2014, Southwestern Ethiopia (n=431). (DOCX 17 kb)
Abbreviations
ART: Antiretroviral therapy; CI: Confidence interval; CPT: Cotrimoxazole
prophylactic therapy; DOTS: Directly Observed Treatment Short course;
EH: Ethambutol and Isoniazid combination; HIV: Human Immunodeficiency
Virus; OR: Odds ratio; RH: Rifampicin and Isoniazid combination;
RHZE: Rifampicin, Isoniazid, Pyrazinamide and Ethambutol combination;
TB: Tuberculosis; WHO: World Health Organization
Acknowledgment
We are indebted to Addis Ababa and MizanTepi Universities for financial and
material supports for the study. We are also grateful to the staffs of study
districts and health facilities for their all rounded supports during the data
abstraction.
Funding
Financial and material supports were obtained from Addis Ababa and Mizan
Tepi Universities based in Ethiopia.
Asres et al. BMC Infectious Diseases  (2016) 16:653 Page 7 of 8
Availability of data and materials
The datasets analyzed during the current study will be available from the
corresponding author on reasonable request.
Authors’ contributions
AA conceived, designed the study, analyzed data and prepared manuscript.
WD and DJ critically reviewed for intellectual content of the study protocol
and manuscript as primary and co-supervisors respectively. All authors
approved the final version of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study protocol was approved by the institutional review board of the college
of health sciences at Addis Ababa University (protocol number 045/14/sph). Since
we did not carry out patient interview or examination, consent of participation
was not sought as the patients were not on treatment at the time of study.
Accordingly an anonymous patient data from routine service registry (unit TB
register) were abstracted upon formal permissions of the health facilities.
Author details
1Department of Public Health, College of Health Sciences, MizanTepi
University, Mizan Aman, Ethiopia. 2Management Science for Health, HEAL TB
project, Addis Ababa, Ethiopia. 3Department of Preventive Medicine, School
of Public Health, College of Health Sciences, Addis Ababa University, Addis
Ababa, Ethiopia.
Received: 26 September 2015 Accepted: 11 October 2016
References
1. Hill AB. Suspended judgment. Memories of the British Streptomycin
Trial in Tuberculosis. The first randomized clinical trial. Control Clin Trials.
1990;11(2):77–9.
2. Arandottir T. Tuberculosis and public health: Policy and principles of
Tuberculosis control. Paris: International Union Against Tuberculosis and
Lung Disease; 2009.
3. British Medical council. Streptomycin for treatment of pulmonary
tuberculosis. Br Med J. 1948;2(4582):769–82.
4. Crofton J, Mitchison DA. Streptomycin resistance in pulmonary tuberculosis.
Br Med J. 1948;2(4588):1009–15.
5. WHO. Treatment of Tuberculosis: Guidelines for National Programmes.
Geneva: World Health Organization; 2003.
6. WHO. Guidelines for tuberculosis treatment in adults and children in
national tuberculosis programmes. Geneva: World Health Organization;
1991.
7. World Health Organization. Treatment of tuberculosis: guidelines. Geneva:
World Health Organization; 2010.
8. Fauce KB, Jameson HL. In: Kasper DL, Fauci AS, Longo DL, Braunwald E,
Hauser SL, Jameson JL, editors. Harrison’s principles of Internal Medicine.
In tuberculosis,16 edn. USA: McGraw-Hill companies Medical publishing
division; 2005. p. 2783.
9. Mori T, Uchimura K, Shimao T. Impact of introducing rifampicin for the
treatment of tuberculosis during the 1970's in Japan. Kekkaku [Tuberculosis].
2013;88(4):417–22.
10. World Health Organization. WHO tuberculosis control program: Framework
for effective tuberculosis control. 1994.
11. Federal Ministry of Health of Ethiopia. Guidelines for clinical and
programmatic management of TB, Leprosy and TB/HIV in Ethiopia. 5th ed.
Addis Ababa: Ethiopian Federal Ministry of Health; 2012.
12. Manabe YC, Hermans SM, Lamorde M, Castelnuovo B, Mullins CD,
Kuznik A. Rifampicin for continuation phase tuberculosis treatment in
Uganda: a cost-effectiveness analysis. PLoS One. 2012;7(6):e39187.
13. Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M, Vernon A,
Lienhardt C, Burman W. Effect of duration and intermittency of rifampin on
tuberculosis treatment outcomes: a systematic review and meta-analysis.
PLoS Med. 2009;6(9):e1000146.
14. Ukwaja KN, Oshi SN, Alobu I, Oshi DC. Six- vs. eight-month anti-tuberculosis
regimen for pulmonary tuberculosis under programme conditions. Int J
Tuberc Lung Dis. 2015;19(3):295–301. i-vii.
15. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis
undertaken by the British Medical Research Council tuberculosis units, 1946–1986,
with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3:231–79.
16. Federal Democratic Republic of Ethiopia Central Statistical Agency.
Population Projection of Ethiopia for All Regions At Wereda Level from
2014 – 2017. Addis Ababa: CSA; 2013.
17. Federal Ministry of Health of Ethiopia. Annual performance report. In: Health sector
development programme iv. Addis Ababa: Federal Ministry of Health; 2011.
18. World Health Organization. Global tuberculosis report. In. France: WHO; 2013.
19. Federal Ministry of Health of Ethiopia. Tuberculosis, Leprosy and TB/HIV
Prevention and Control Programme Manual. 4th ed. Addis Ababa: Ministry
of Health of Ethiopia; 2008.
20. Southern Nation Nationalities Peoples Region Health Bureau (2014). "Health
profile of Southern Nation Nationalities Peoples Region." Tuberculosis. 2015,
from http://www.SNNPRHB.gov.et. Accessed 28 Oct 2015.
21. Centers for Disease Control and Prevention(CDC) (2011). "Epi Info™, a
database and statistics program for public health professionals." 7. from
http://www.cdc.gov/epiinfo.
22. World Health Organization. Definitions and reporting framework for
tuberculosis – 2013 revision. In. Switzerland: WHO Library Cataloguing-in-
Publication Data; 2013.
23. StataCorp. Stata: Release 13. Statistical Software. 13th ed. College Station:
StataCorp LP; 2011.
24. Tessema B, Muche A, Bekele A, Reissig D, Emmrich F, Sack U. Treatment outcome
of tuberculosis patients at Gondar University Teaching Hospital, Northwest
Ethiopia. A five - year retrospective study. BMC Public Health. 2009;9:371.
25. Munoz-Sellart M, Cuevas LE, Tumato M, Merid Y, Yassin MA. Factors
associated with poor tuberculosis treatment outcome in the Southern
Region of Ethiopia. Int J Tuberc Lung Dis. 2010;14(8):973–9.
26. Berhe G, Enquselassie F, Assefa A. Treatment outcome of smear-positive
pulmonary tuberculosis patients in Tigray Region, Northern Ethiopia.
BMC Public Health. 2012;12:537.
27. Feng J-Y, Su W-J, Chiu Y-C, Huang S-F, Lin Y-Y, Huang R-M, Lin C-H,
Hwang J-J, Lee J-J, Yu M-C, et al. Initial presentations predict mortality
in pulmonary tuberculosis patients - a prospective observational study.
PloS One. 2011;6(9).
28. Wang CS, Chen HC, Yang CJ, Wang WY, Chong IW, Hwang JJ, Huang MS.
The impact of age on the demographic, clinical, radiographic characteristics
and treatment outcomes of pulmonary tuberculosis patients in Taiwan.
Infection. 2008;36(4):335–40.
29. Kayigamba FR, Bakker MI, Mugisha V, Gasana M, Schim van der Loeff MF.
Sputum completion and conversion rates after intensive phase of
tuberculosis treatment: an assessment of the Rwandan control program.
BMC Res Notes. 2012;5(357).
30. Bernabe-Ortiz A, Carcamo CP, Sanchez JF, Rios J. Weight variation over time
and its association with tuberculosis treatment outcome: a longitudinal
analysis. PLoS One. 2011;6(4).
31. Hoa NB, Lauritsen JM, Rieder HL. Changes in body weight and
tuberculosis treatment outcome in Viet Nam. Int J Tuberc Lung Dis.
2013;17(1):61–6.
32. Horne DJ, Royce SE, Gooze L, Narita M, Hopewell PC, Nahid P, Steingart KR.
Sputum monitoring during tuberculosis treatment for predicting outcome:
a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(6):387–94.
33. Daniel OJ, Alausa OK. Treatment outcome of TB/HIV positive and TB/HIV
negative patients on directly observed treatment, short course (DOTS) in
Sagamu, Nigeria. Niger J Med. 2006;15(3):222–6.
34. Shaweno D, Worku A. Tuberculosis treatment survival of HIV positive
TB patients on directly observed treatment short-course in Southern
Ethiopia: a retrospective cohort study. BMC Res Notes. 2012;5:682.
35. Maher D, Harries A, Getahun H. Tuberculosis and HIV interaction in sub-Saharan
Africa: impact on patients and programmes; implications for policies. Trop Med
Int Health. 2005;10(8):734–42.
36. World Health Organization. WHO policy on collaborative TB/HIV activities
Guidelines for national programmes and other stakeholders. Italy: WHO
Library Cataloguing-in-Publication Data; 2012.
37. Uyei J, Coetzee D, Macinko J, Guttmacher S. Integrated delivery of HIV and
tuberculosis services in sub-Saharan Africa: a systematic review. Lancet
Infect Dis. 2011;11:855–67.
Asres et al. BMC Infectious Diseases  (2016) 16:653 Page 8 of 8
